Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576763 | 0.88 | KDM4E (0.60) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL29275411 | 0.87 | KDM4E (0.65) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3916832 | 0.86 | KDM4E (0.49) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2913617 | 0.86 | GAA (0.49) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2912901 | 0.85 | GAA (0.48) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2909352 | 0.83 | KDM4E (0.64) | KDM4EALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL30576794 | 0.83 | GAA (0.55) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3926162 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2776747 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2350825 | 0.81 | LMNA (0.62) | KDM4EALDH1A1MEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126153-A | New coronavirus inhibitor, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-11-28 | — | — | CN | disclosed |
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| EP-2038253-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1940786-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007138242-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007031791-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | NR4A1, NR0B1, NR1H4 | KDM4E 4293/4885ALDH1A1 441/4885GAA 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.